Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

C B m E & U

C B m E & U artwork

Genomic Newborn Screening: Where less really is sometimes more with Ainsley Newson

Aug 25, 202655 minAudio
ShareXLinkedInFacebookWhatsAppEmail

Send us Fan Mail Did you know that genomic sequencing can now screen newborns for hundreds of rare conditions right at birth? That looking too closely at our DNA might actually cause more anxiety than answers? And is there such a thing as knowing too much about your health before you've even taken your first steps? Professor Ainsley Newson (University of Sydney) joins the podcast to discuss the complex ethics of genomic newborn screening programs. Ainsley shares some delightful anecdotes about her first impression of Sinead, and unpacks how looking at a baby's DNA differs from traditional biochemical tests, what it means to balance the "value of knowing" against screening-related harm, and why we need to prioritise solidarity over high-tech hype. Remember people, be savvy!

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Transcript

From the show. Tap a time to play from there.

SPEAKER_00The center presents a new podcast, C BME and You, a podcast devoted to promoting awareness and debate around controversial ethical issues in biomedicine.

SPEAKER_01Welcome back to CB Me and You.

SPEAKER_02I was in the middle of telling Aid's like, just watch out, he's gonna be loud. He cut me off. I visibly freezing. Please continue.

SPEAKER_01Welcome back to CB Me and You, a podcast about bioethics. Today, do you have health issues that you wish you knew about all the way back when you were a baby? Or would you prefer to never have known about them? That's what we're gonna talk about. And joining us today for this discussion is Professor Ainsley Newsen from the University of Sydney to discuss genomic newborn screening programs.

SPEAKER_02Welcome, Ainsley.

SPEAKER_01Hi.

SPEAKER_02Are you okay?

SPEAKER_03I'll be fine.

SPEAKER_02It takes a minute for the shock to wear off. I really need to put a disclaimer at the start. Josh uh James will be loud.

SPEAKER_01I don't know why you have to disclaim to any guests.

SPEAKER_02I think it's like a health, like a health risk. Like you might burst someone's eardrum on it.

SPEAKER_01I don't usually go that loud. I just did it to like hang yourself.

SPEAKER_02Welcome, Ainsley. I'm so excited for you to be here.

SPEAKER_01Thank you.

SPEAKER_02Uh listeners, Ainsley and I go a few years back now. I would say that you are one of my excellent friends. I'm so excited you're in Singapore. But my first question for you is not how uh would you rate me on a scale of one to ten of friendship? It is in fact coffee.

SPEAKER_03I didn't have a choice. When I first met Janae, the first thing you said to me is we are going to be friends forever.

SPEAKER_02And so she's when I was to answer that question. Yeah. It's a ten. Okay, okay, okay, yes. Okay, now everyone knows knows me very well. Uh, first question coffee or copy?

SPEAKER_03Coffee. Okay. So with the caveat that I tried copy for the first time about eight minutes ago. And I enjoyed it, but uh I'm from Melbourne. So there is really nothing else to say. I've spent my life downloading apps to find good coffee in all parts of the world.

SPEAKER_01Yeah. Funny thing is that we have about 10 listeners, I want to say, uh, or maybe 20 or so, who are either from Australia or know Australia very well. The moment you said I'm from Melbourne, they're like, ah, yeah, I've heard this before.

SPEAKER_02And then another hundred or two hundred who are like, uh so Australians are, for our listeners, Australians are very snobby about coffee. But at the top tier of that snobbishness is Melbourne's. Yes. And Ainsley, that is where you said.

SPEAKER_03Although the top coffee in the world last year or the year before was Sydney. Dun dun dun. So watch out because we're coming for you, Melbourne.

SPEAKER_02Okay, excellent. Um, and I do know that your coffee order is magic.

SPEAKER_03Yes. From fairly recently, with thanks to a health law colleague, Professor Mark Taylor, who is a British person living in Melbourne. He told me about it. Because I've been gone from Melbourne for more than 20 years, and the magic has arisen since then. And what a sentence.

SPEAKER_02The magic has risen since then.

SPEAKER_03But anyway, it's long story short, is it's like a flat white, which is a contested coffee between Australia and New Zealand. And uh, but it's more than a piccolo less than a flat white, similar to a cortado, if you are familiar with certain European coffees.

SPEAKER_02I would like to double down on being Australian and snobby and say that one of my gripes with Singapore, there are very few, one of them is that you can order an iced flat white in this country, and I just don't think that exists.

SPEAKER_03Isn't it just kind of like an iced latte?

SPEAKER_02Yes. Yeah. But unbelievable. Makes me angry. I got no words, I'm just that angry. My next question is what country do you want to travel to next?

SPEAKER_03Oh, like one in 25 Australians, I'm very scared. Yeah. I've already been there twice in the last two years, and I'm it I just wanted more. Like I just love it, and it's so cliched. And I'm learning Japanese on Duolingo and doing all the things and going skiing there like everyone else. But it is just fabulous, and I really enjoy being there and spending time there. But so that's probably top of the list. Uh but plenty of other places besides probably Vietnam as well, because I've not been there and keen to go.

SPEAKER_02Uh, once you get adapted to like the motorcycle beeping in cities like Hanoi and Ho Chi Minh, honestly, amazing. Oh, the best, really good coffee. Not quite Australian, but I'd put it in a separate category. Anyway, before we digress back to question one, I'll move on to question three. What song would you sing at karaoke?

SPEAKER_03Oh, I've spent longer than necessary thinking about this, and I haven't got a clear answer. But what I will say is I did do karaoke recently when I was in Japan with my 14-year-old. And one thing I will say is it's much harder than it looks. And you there's songs that you pick because you think, you know, you know them, you sing along to them all the time, but having to do it with the appropriate notes and timing is extremely hard. Like, hats off to you, Taylor Swift. You make it look very easy, and it is not easy, but I sing a lot in the car because I have teenage kids and I drive them all around the place.

SPEAKER_03And so I'm gonna say two songs just because they're things I sing generally with my kids. So my oldest child is a bit of an old soul, and he loves the Beatles. And so In My Life by the Beatles is a beautiful song from Rubber Soul. I'm not going to sing it too.

SPEAKER_02Yeah, I'm gonna get one of these guests one day.

SPEAKER_03And so that's a beautiful song. It's really melancholic, but also quite uplifting, and it was sort of the Beatles kind of move away from like pop into slightly more, you know, stuff that took them in a different direction. And then my 14-year-old, I'm not allowed to listen to anything in the car that's too happy or too poppy. So she likes dark songs uh and kind of things that are really slow and moody. So she's really into Lana Del Rey. Um, and I think it's called National Anthem, but I don't know if that's the actual name of the song.

SPEAKER_03But anyway, so we sing a lot of Lana Del Rey. So I'm getting really down into my alto and tenor kind of register with her, and then I get told off for singing because it's not about me.

SPEAKER_02Mom, Mom, step aside.

SPEAKER_03Yeah, just Mom, embarrassing me myself. Mom.

SPEAKER_02When is your turn?

SPEAKER_03When I'm in the car by myself or in 10 years' time.

SPEAKER_01So a couple of takeaways from that. Firstly, uh, yes, Taylor Swift, you know you're out there. We know you're listening. Um, yeah, shout out from one of our guests. Uh second, second point. So it sounds like you wanna have more practice. Hypothetically, you know, we practice karaoke.

SPEAKER_02Would you actually join us one time?

SPEAKER_01Yes. Got him.

SPEAKER_03Yes. 100%, yes.

SPEAKER_02Okay, okay. We will try to squeeze this in in the next 48 hours.

SPEAKER_03But maybe next time. I'm feeling pretty booked up, actually.

SPEAKER_02We'll see. Would you look at that time? You gotta go.

SPEAKER_01Maybe next time. On your way to Japan.

unknownYeah.

SPEAKER_02Because we're still on the way.

SPEAKER_01On the way from Australia?

SPEAKER_03Ish. No, it's not. I might be back in Singapore later this year. Oh, excellent. So we watch this space.

SPEAKER_02Hold hold a watch just one. It doesn't even have to be an evening. We could just pop out for lunch. As long as you don't have to talk after that.

SPEAKER_03NUS has got everything. Surely it's got a karaoke place as well.

SPEAKER_02Actually, um, James and I have explored some of the different uh studio spaces on campus, and the majority of tutorial rooms say this is not for playing music or singing to.

SPEAKER_03While I was lost on the way here today following the yellow ceilings that stopped and I ended up in the sports center, I did find an esports room, the NUS Esports Club. So I reckon karaoke card has esports. Well, I reckon if you're allowed to play a video game, how how different is a karaoke song?

SPEAKER_02Yeah, I second that. Conceptual analysis, what does esports it show like so much vocal work, so much core. I'm in. Okay.

SPEAKER_01There also isn't karaoke plays at NUSS.

SPEAKER_02Oh, there is! So NUSS is isn't it a club or whatever? Yeah, it's like the alumni society. We could use Julian's membership to get in. He won't join us. He said, Over my dead body, would he do it again?

SPEAKER_01Okay.

SPEAKER_02Which implies there was a first. We get to find out what happened.

SPEAKER_03All this space.

SPEAKER_01Yes. We'll get to the bottom of it.

SPEAKER_03I definitely sang karaoke in Japan with a bunch of bioethicists in the late 90s, and Julian was at that conference, but I cannot remember if he came or not.

unknownWhat happened?

SPEAKER_03I think it was. What did he do to him? No, no, nothing. But it was people that really didn't know each other well and doing that as one of the first things you do when you've met someone for the first time, another colleague whose work you really admire. It's pretty the awkwardness is very high.

SPEAKER_02I was gonna say classic bioethicist, particularly on the East Coast, jumping from zero to a hundred. I mean, that's just me going, I will be friends with you. That's just you. Yeah, yeah, that's fair. I may have colored that perception. Let's get started. Okay. So our very first question today is can you just tell us what is newborn screening and what makes genomic newborn screening a bit different?

SPEAKER_03Okay. So newborn screening is a form of population health. And I say population rather than public because it's aimed at a specific population. And it's what we call a screening program. It's a program that is designed to find the people that need to be found. So screening is like a sieve. So you throw uh stuff into the sieve, and depending on how big the holes in the sieve are, things either go through or not. And you want the people to go through that need to be found and the people that don't need to be found to stay in the sieve, basically.

SPEAKER_03So newborn screening is a program that exists in many high-income countries globally, and it detects certain conditions at birth in using a card called a blood spot card through a tiny sample of blood that's taken from the heel of the baby within the first few days of birth. And that sample is tested largely using biochemical means at the moment to work out whether a baby might have a higher chance of developing certain conditions. And then, of course, that requires clinical confirmation and follow-up with lots of different services.

SPEAKER_03It's been established for over 50 years, it's very successful, it's definitely saved lives, it has high public trust wherever it's offered, and uh it tends to be organized by governments and public health agencies generally. So, as to what might make genomic newborn screening any different, that's quite a contested question. And on the one hand, you can say uh so what we're talking about here is the potential augmentation of existing newborn screening programs by adding in a way of looking at the baby's health by looking at their genome instead of say measuring biochemical analytes in the blood.

SPEAKER_03So you just look at the DNA instead, or as well. We don't, there's lots of different ideas about what this could look like. And at the moment, uh some are saying there's nothing to see here. This technology is not exceptional, you're just hyping it up. Um, it, you know, we've we can always see more than we can find, that that than we choose to find. That is what newborn screening is, or that's what any screening is. You always have a modality where you're looking at certain things, whether it be imaging or biochemistry, where you could look and find more than you actually do.

SPEAKER_03I think what at least kind of intuitively makes genomics seem something we need to definitely pay attention to and might maybe change how we think about newborn screening is um firstly it is hyped. I'm not necessarily to endorse that, but it is a fact that it is hyped and lots of people are interested in it. And so what we have to do is choose to use it well, as and when we decide to use it. But it could also generate quite a lot of information, it might generate information that's uncertain, although, of course, biochemical results are uncertain too.

SPEAKER_03And um it might predict things that happen in the future, it will have implications for other family members, but as does many types of existing screening too. So it kind of does make it different and it doesn't. I think conceptually, if you really unpack it, you will always find another example that has similar properties. But I also think collectively there's also kind of slipperiness between what makes something screening and what makes something a precision health program and part and also genomic sequencing is a technology that's rapidly being rolled out across clinical care mainstreaming.

SPEAKER_03And so because it's kind of a similar way of sort of going in and looking for particular variants, that kind of approach is being used in lots of different parts of healthcare. Whereas, say, with biochemical screening, we don't typically sort of do the type of test we do in newborn screening in other parts of clinical care at the moment, anyway. So that's a hot mess. And so I would say all things considered, the proof of the pudding is in the eating, as you say, in the sense that I I was recently part of a review of um ethical, legal, and social issues to do with the use of genomics in newborn screening.

SPEAKER_03And that review identified more than 300 papers. So enough people think this is interesting and warrants conversation that I think, you know, regardless of whether it's different, it's important and it's worth paying attention to, including from an ethical perspective.

SPEAKER_01So you you mentioned that newborn screening has been around for 50 years. Just to create a timeline in our heads, uh, how new is this genomic newborn screening and what are some of the uh I guess uh in what way is it changing the most in terms of both the science and the way we talk about this?

SPEAKER_03Yeah. So uh just to clarify, uh apart from maybe one place globally, no one has yet implemented genomics in a formal population-based screening program. Um I think, at least for newborns, there has been some genetic screening programs in the past, but they've been targeted to certain groups that have uh an increased chance of a certain condition. So uh premarital screening in Cyprus, for example. But in terms of newborns, um, existing conditions that are looked at in newborns, genetic-based testing is kind of used for one or two conditions.

SPEAKER_03So in Australia, where I live, uh we are in the process of bringing in um testing nationally, all newborns for spinal muscular atrophy, SMA, and that is a gene-based test looking at certain variants. But back to your question, uh what's changed and when? So the the kind of thing that kicked all this off was the advent of next generation DNA sequencing, which is so-called high throughput sequencing. Happened early 2010s, sort of 2010, 2012, 2013 type time.

SPEAKER_03And basically, before then, to get any information about a person's genome, we had to do it in a really slow and painstaking way. It was quite accurate, but you could only do sort of three, four hundred base pairs at a time, and you had to stick it all back together, and it was really, really slow.

SPEAKER_01Out of how many base pairs?

SPEAKER_03I have no idea, but like tens of thousands. Um, so it was really, really slow. And you couldn't sequence an entire gene. You had to be really assiduous with what you chose to look for, and it just meant the scope of testing was quite limited. And what next generation sequencing does is it uses big machines, it effectively chops the genome up and uses bioinformatics to stick it all together, and each tiny fragment is sequenced now up to like 30 times per sequence, and use reference genomes to stick it all back together. And uh we now even have long read sequencing.

SPEAKER_03So the fragments that these machines can sequence are getting longer. And so basically, faster, cheaper, the accuracy is pretty good now. Certain areas of the genome are hard. Um, this is probably more than you need to know. But uh ultimately that technology has led to lots of questions about where we can deploy this. Because alongside all of this, so I'd say that's happening. So we've got new technologies, and we're we're looking for ways where they can augment what has come before to maybe make it better.

SPEAKER_03Um, but also there's lots and lots of people globally, hundreds of thousands, if not millions of people, probably millions living globally who are undiagnosed and they have rare conditions. And these are individually rare but collectively common. And that community has spent a long time being misdiagnosed, finding it hard to access care, um, not having any treatments available, etc. And this technology offers a lot of hope for people who live with an undiagnosed condition.

SPEAKER_03At the same time, it's not a magic bullet. The diagnostic yield of genomics is not 100% and probably still around 50% or so. But don't quote me on that, even though I'm literally on a podcast. Um, and so You're quoting yourself on it. I am, but ultimately, you know, there's a lot of hope there. Uh, and that's it's hope, but it also gives rise to attention because part of the thing about screening, if you go back to that sieve analogy, is every time we make a hole bigger in the sieve, we let more people through.

SPEAKER_03And they're all people that are going to need follow-up, extra confirmation, transition into clinical care, access to treatment. But the rarer the condition, sometimes also, the less well we understand some of the variants or the changes in the genome. And so our line between a change that we see in the genome and predicting what that might be like for that person can be really hard. And also, we know that a lot of the knowledge we have about the genome has come from uh having studied people that are unwell.

SPEAKER_03And what we found once we started looking at the genomes of people who aren't unwell is that a lot of us are walking around with these changes as well. And so it kind of blew open a little bit our our confidence about prediction. So I don't know if that's actually answered your question. Uh it's a bit of a potted history, but ultimately it the the impetus for thinking about the use of genomics in newborn screening is to increase the yield of screening. So making those holes a bit bigger, but trying to do so in a way that still finds people that need to be found and try very hard not to find people that don't actually need that follow-up, which we'll probably come back to, I think.

SPEAKER_02Yeah. So leading straight on from that, what have we traditionally, like what things or criteria have we traditionally used to identify what should be screened and importantly what should not be screened?

SPEAKER_03I really want my uh security blanket laptop right now, but uh I won't. So uh in the late 1960s, uh two people called Wilson and Jungner published screening criteria.

SPEAKER_02I've been calling it Jugner or you might be correct. No, no. Okay.

SPEAKER_01I've been calling it Wilson.

SPEAKER_03Let's go with Jungner. Okay. W and J, as we refer to them sometimes in our shortcut notes to each other when we're writing papers. Um they developed screening criteria for all screening for the World Health Organization. And they remain really prevalent to this day, but they're not adopted wholesale. Um, but they say, they say, I think there's about 10. There's probably more slightly, there might be different number than that, but it's around 10. Things like the condition needs to be an important health problem, there needs to be a test, the test needs to be acceptable to the population, you need to be able to do something about it.

SPEAKER_03Um, there's, you know, there needs to be kind of validity and utility, etc. And um so those those kinds of questions basically it's designed to kind of stop you using bad tests at scale and those and also doing tests that people don't like or aren't acceptable. So it also has cost uh cost effectiveness considerations and things like that. And and those kinds of criteria have been augmented and adopted. There is a literature that's been around for about 15 years that sort of troubles those criteria when it comes to the use of genetics and genomics in screening programs, but also just newborn screening generally, because um one of the things with the rare condition aspect is that there isn't always great characterization of the condition.

SPEAKER_03So it can be, you know, what makes something important or not, what makes the test a good test. Sometimes the lack of research because it's so rare can mean the level of confidence can be lower. But at the same time, you have so that you know hundreds of thousands of people, if not millions, globally, who live with a condition that could be helped if we had the knowledge. At the same time, I don't want to oversell the power of genomics here. Uh, genomics is one tool in our toolbox.

SPEAKER_03It is telling us that there's something different in a genome. It is not a diagnosis. Uh, it can be wrong. It often is wrong, and it requires a lot more confirmatory work up. And that's also a consideration when we think about trying to deploy this at scale. We don't just add in all variants we could possibly add. We don't just routinely give people information that has uncertain significance in a screening context. Context because it doesn't meet the reason we're doing screening, which is to find the people that need to be found.

SPEAKER_03And but you know, there is contestation coming through around things like well, what about the value of knowing? What about empowerment through information? Um, what about uh our ability to maybe not help the newborn themselves, but help the newborn's family or find an older sibling that needs to be diagnosed to, or things like that. And so a lot of the things around those original screening criteria are kind of lying in tension now because we have tools available, including genomics, that sort of push against the criteria a little bit.

SPEAKER_03So the question then becomes: do we change the goals of screening because we have new technologies? Do we allow our screening decisions to be led by technology, or should we actually keep the aims of the screening program at front of mind all the time and kind of accept that screening can't find everyone because that's not what screening does. It is a screen and it will always be imperfect, even with really fancy technologies behind it. So um, yeah, so I think ultimately what we've also done, I'll say this one more thing as well, is we've tended to go into screening by what we call a condition-by-condition approach.

SPEAKER_03So you, as a person who's interested in screening, you approach government and say, why aren't we screening for condition X? And then it goes through a whole evaluation. And obviously, tools like um tandem mass spectrometry and genomics allow us to look for lots of things at the same time. And that's another reason why people are saying, well, the way we've done it up until now might not really work. But no one's really got to consensus yet on what it might be replaced with and how we should do that, while at the same time not causing more harm than good.

SPEAKER_03So uh we were at a workshop yesterday, and our colleague Angela Ballantine mentioned a really famous quote from Muir Gray. It's from a paper Muir Gray co-authored in about 2008, and it's all screening programs do harm. Of those, some do good as well. And of those, some do more good than harm at a reasonable cost. And that's kind of what screening is all about. It's about that messiness of trying to deploy these really powerful instruments well in a population who, by definition, are asymptomatic, are completely, you know, not expecting to be found, have no family history of any relevance.

SPEAKER_03And you're trying to use these fairly coarse tools to actually, you know, get those people through the holes when they need to go through. And I should say that Civ analogy is not mine. Um, it comes from a really famous screening textbook that Angela Raffle and others have published, and it's an excellent book.

SPEAKER_01So you talk about uh like rare diseases, and I guess that's one really obvious use of it. But one thing that my I was thinking about uh when you were talking about this whole criteria is you know, what about a whole range of things like mental disorders or even like subclinical mental disorders where you know you have something that people would gonna have reasons to be interested in and want to find out, but at the same time it it's you know, the the link between the genetics and the um and the and the disorder are there, but it's not as clear.

SPEAKER_01So well, where do we want to put that?

SPEAKER_03Yeah, I would ask you a few questions in reply. Uh the first one I would say is why the newborn period for that information? So newborn screening is all about generally focusing on early life, trying to find things where you have an intervention that will benefit the newborn at that point in time or fairly soon after. And also going back to something I said earlier, we want the test to be good. So, how would you feel about deploying a test where there maybe wasn't a huge amount you could do about it at that point in time, and then actually, when you know that test is clinically available later, lots and lots of people choose not to do it.

SPEAKER_03So I think, you know, going there's a that criteria about it being acceptable to the population. I think we really want to use an instrument like newborn screening to find things that are, you know, serious, uh able to intervene, health issues that generally present early in life and where you can take it a step to intervene and mitigate. So I would say uh mental ill health is not something that newborn screening is designed to solve.

SPEAKER_03And it is uh probably something that needs better literacy among treating health professionals, early intervention programs, uh phenotypic screening, down the track, etc. It's not necessarily an area of health that I feel, at least at the newborn stage, genomics could help. With that said, there's a really burgeoning psychiatric and mental health genomics kind of clinical provision happening, and it's offering a lot of empowerment and um I guess acceptance and understanding to people who live with mental ill health.

SPEAKER_03So I don't in any way want to discount the value of that. I just don't think that's what newborn screening is for.

SPEAKER_01But hypothetically, if there was psychotherapy for babies, then this would be useful.

SPEAKER_03At the time when there is psychotherapy for babies, I'll happily come back and have that conversation with you then.

SPEAKER_02Bebe pops out straight to counselling.

SPEAKER_01Yeah, you know, you want to nip the pro problems in the mud.

SPEAKER_02Um, so I uh I'm I'm aware that newborn screening was primarily for early onset and treatable conditions. We were trying to identify people that we could prevent their conditions before it was almost irreversible or too late to do something about it. But genetic testing is allowing us to identify predictions for maybe mid-childhood, adolescence, even like post-age of consent, well into your 20s or 40s. And so is this expanding the scope of newborn screening too far?

SPEAKER_02Or to quote my favourite Missy Higgins song, are we trying to squeeze a circle through a triangle? Or is it a square through a circle? Oh my goodness.

SPEAKER_03I've lost my Australian card. Uh no, and also our other fan, Missy Higgins. We're very sorry, Missy, that we've misquoted your song lyrics.

SPEAKER_02Tango, triangle through a circle. I think. I don't know why I'm looking at all three of you for this confirmation. This is clearly my niche.

SPEAKER_01Maybe Taylor Swift, you can weigh in anytime in the comments.

SPEAKER_02Anyway, are we trying to squeeze too much out of new box screening with this?

SPEAKER_03Yeah. I'll answer first as kind of how the field is grappling, and then I might give my view as well. So the field as a whole, this is a really interesting tension right now because I think it really brings to a pointy end the moral significance of the value of knowing and the point at which that knowledge should be offered. And so, you know, for example, um, there are some conditions where they I have just completely lost my words.

SPEAKER_03They have variable expressivity. So, in some, you know, some forms of the condition are really um very severe, like categorically severe, no sort of argument about it. But then other forms of the condition are more mild and also variable onset. And sometimes those conditions do end up in newborn screening and it can be quite hard to predict. But a decision is made on balance that actually the severe forms where it does happen is important enough to warrant that harm-benefit trade-off. So um SMA, which I mentioned earlier, it's a it's actually quite a complex condition genetically.

SPEAKER_03You have to kind of test two genes and the genotype, phenotype uh kind of matchup. It's it's kind of there, but there's also a lot of grey. And so certainly in screening babies for SMA, we are definitely finding babies that might not actually develop severe SMA. We will definitely find babies that will as well, and that's why we're doing it in Australia now, because there's a treatment when they didn't used to be. But we have to make that trade-off. And so the further down that track you go, it's kind of that mission creep or edge creep, you know, like, well, we can do this one, then why don't we do this one?

SPEAKER_03And and patients tell us they really value this information, so why aren't we giving it to them? Uh, I spent a really long time being diagnosed, and if you just told me at birth, then I would have this. I think that's asking a lot of families to remember and impart that information down the tracks, especially if it's something like carrier information or something that won't onset until later. So, but so I think we have to do more work on what this value of knowing means. And there's no consensus yet.

SPEAKER_03Um I feel what I would do with for my own perspective is I think if we make this too complicated, we risk undermining why we're doing this in the first place. So we are doing this to with the first and foremost aim to find babies that will become really unwell and to do something about it, or young children who will become very unwell and to do something about it. And sometimes we cannot do that without also finding babies that maybe will get that information but won't ever become unwell.

SPEAKER_03And we have to just care for them and make sure they're reassured with their clinical follow-up, which is an important equity consideration for newborn screening to make sure that they get that care and follow-up. Um, but so I would sort of say things that start to look more like only later onset or only milder presentations, or things where there might be a different opportunity to offer this information at a later point in time. We don't need to do everything at birth.

SPEAKER_03I think, you know, let's not get ahead of ourselves. It's because if we do and it gets too complicated, asking people if they want to have it is going to be a big challenge and getting people to agree to it. And generally when we do screening, we do it because we think it's a good thing to do. And we're making that screening offer with an assumption that it's, you know, you frame the offer to the population with the the kind of messaging that this is a good test and you should choose to have it. There's also a bit of conceptual blurriness happening between screening as a formal systemic population thing and precision health.

SPEAKER_03Because going back to the hype thing, you know, precision health and the role that genomics will play in that, there's a lot of discussion around sequencing newborns as well. I would say a lot of that discussion that's happening is not actually as a screening paradigm. They're talking about it much more about bespoke um clinical intervention.

SPEAKER_02Just to clarify for our listeners, precision health in in your terms is Huh. Or so I'm sure our listeners all know. The way my brain just go back to podcast number 14 with the way my brain thinks about it is basically like sequencing a baby's genome, and then the way it's pitched to a lot of us is, and then you have that genome for life. Yeah. And we can consult that genome uh later on to see if you might be predisposed to like allergic reactions to a particular drug, or if you hit 21 and you're starting to experience some health issues, just go back to the genome and I'll tell you the answer.

SPEAKER_03Yeah, it's kind of the so-called lifetime health resource, which is probably beyond the scope of what we want to talk about today. But uh yeah, I mean, precision the notion of precision health very broadly is the right intervention for the right person at the right time, using resources that are collated in advance and held in an accessible way across the health system. So perfect.

SPEAKER_02I could go on a textbook.

SPEAKER_03There you go. Well, that's probably where I got it from.

SPEAKER_01So you talk about harms, right? Um, and you you've kind of suggested that there are multiple harms of like related to using resources in a really bad way, uh doing things that are just not cost effective, or things that uh we don't have interventions for, so it's like, you know, what's the point? Um I'm interested to know a little bit more about what are the kinds of harms that can exist for the individuals who we're screening for, you know. Like, yeah, so that there's this saying that I'm I'm sure many people people say, but what's the harm in just knowing more about my own genes and the knowing the kinds of risks that might exist in the future for me?

SPEAKER_01Well, why won't you tell me that?

SPEAKER_03Yes, and that rhetoric definitely exists. And I'm I think we have to critically engage with it really carefully. And uh I think we are also uh as a population, we're just you know, it's very understandable. We all pretty well uncritically think that information is good. And we all love tests. Tests are great, they help us, they tell us what to do.

SPEAKER_02What do you mean tests are great? No, no, not as in academic tests, as in clinical flashbacks. Yes, sorry, Sinead. We'll just get you a law school is not too far away from me.

SPEAKER_03Yeah, we'll get you a paper bag. Testing, as in uh giving people a medical test to tell them something about their health. We are all predisposed to want that, and we find it quite hard to understand that uh that information might be somehow inside us and there was an opportunity to get it out and we didn't. So why didn't you? And I will say it's tricky. Uh what I will what I will also say is that it it we have to having that offer assumes a lot of things.

SPEAKER_03It assumes really high health literacy, it assumes lots of clinical resources to be able to curate all the variants in diverse populations. It assumes a lot of resources to impart that result uh and that people will remember it and use it over time, that it will be stored securely somewhere and be drawn on when required. We're also going to assume that the result is true and real and will give us what we need to know and that we can do something about it. So I think we tend to kind of just assume we have information, therefore we have health.

SPEAKER_03And I think that line is not, it's neither direct nor unbroken. And so, what ways of thinking about this that draw on things like public health ethics, which I've written a lot about in my work on screening and screening ethics, say is that we just can't think about it as a sort of, I'm an individual, I want this information, give it to me. Because once you expand that out to every baby born in a particular country in a year, it suddenly starts to look a lot more complicated.

SPEAKER_03And so what we want to do is, yes, impart that information where it will make a difference and help someone, but our ability in the context of systemic screening to do that has to hang together as a program. And you have to think of it from the end to end, from the first discussion about what it might do, to ensuring that someone is not lost to follow up and has access to what they need. Um, and you know, even in a country like Australia that has some public health care rapidly decreasing and hard to access and expensive when you can't get it, is you know, there are a lot of barriers, um, not just geographic but economic as well.

SPEAKER_03So, yes, we can, to go back to your question, James, we can give people stuff that they value, but let's make sure that what we're offering is high-quality information, able to be understood and in and used by the people we're offering it to, and that it funnels them into follow-up processes that are equitable. And I don't think we are anywhere close yet to a point where we can just do that wholesale.

SPEAKER_02I was just gonna say, like, um, imagine being told that um you have a variant in this particular sequence at SQ231. I forget how to write sequence points or low-kive.

SPEAKER_01SQ231. Isn't that a flight to Sydney or something?

SPEAKER_02Probably Singapore Airlines. Can't afford that. Like, um imagine being told you have an uh you have a variant, maybe like a hundred people generally have this variant. We're not actually sure what that will look like for you. And if someone was to say that to me, that would not bring me any benefit. It might actually just make me a little bit anxious. Like, I'm a bit different, is it? So I can see your point that there we can't just go around telling everyone every single bit of genetic information because not all information is meaningful.

SPEAKER_02And unless we can prove a really solid, consistent benefit across the board, then just giving people, you know, all this additional extra information about variants is probably like not really justified at that sort of level.

SPEAKER_03Not for the investment that it will require to do that, especially if you're using public funds. So I mean, a separate question is whether people want to spend their own money to do that and what that might look like. And I guess my answer to that would be where do all those people end up? Uh they go back into a health system where a payer of some kind, whether it be an insurer or a government, pays for the follow-up for all the information they receive in that private care. So you put it really well. I I have no notes.

SPEAKER_02I I also was gonna say that um your point about we're making presumptions about health literacy and about how how much people truly understand when they're told something about their DNA or their genes. And I think so much of the problem is that what most of us remember from school being told about DNA is that it's a blueprint for life. And we all we look at blueprints and then we see the building. Bold of me. You know, we see we think blueprint, we mean, or we get told it's like an ingredient list or an instruction list. And if you follow the recipe, then you'll get the product.

SPEAKER_02That is not an accurate metaphor. Maybe if we just updated that a little, we might have less presumptions about, you know, genotype to phenotype, or you know, like uh the the gene for eye colour and then what your eye colour actually is. Yeah.

SPEAKER_03And I think, you know, they're very powerful, those images, but they're not accurate and they're increasingly inaccurate the more we know. And um a shout out here to Annika Lucason, who's professor in Oxford, has is worked a lot on genomics in newborn screening, and I really admire her work in this field. And she, in conversations with me, has sort of said things, because you know, in my paper, I have a tendency to kind of write like until we have knowledge. And she goes, Heinzla, you know, like you know, we won't ever, like we're never going to get to a point where we say we can we now have knowledge.

SPEAKER_03Like it's just it's not how it works. It's very, very complex. And the more we know, actually, the harder it is, and you know, and let alone bringing in, you know, epigenetics and all the rest of it, and you know, just social determinants of health and everything else that sits on top of that. I also want to say this doesn't mean don't do it at all. It you know, don't throw, you know, don't throw it all away. But at the same time, it's that argument for sort of being really mindful and conscious of adding value to an existing, very, very effective, highly trusted program that works and keeping that front of mind.

SPEAKER_03Or if you're gonna go and do it, call it something completely different and do it in a different paradigm.

SPEAKER_02DNA is not shiny, it is a messy, blurry fuzz of lint that you find in the back of your c your closet and you go, where did this come from?

SPEAKER_01And sometimes it's a random spider that bites you.

SPEAKER_03And then you have superpowers.

SPEAKER_02Um I I know I'm hogging a lot of the question shame, so I got I got another one. Um I saw this, I saw this uh statistic or this fact in in a paper, I think it was yours, that said that there are these pilots popping up all over the world. And I saw that the number of conditions they screen for is between 180 and 604. How is a parent meant to grasp this and then consent to it?

SPEAKER_03Okay. I feel like every question you ask me, I'm going, okay, I'm gonna start that with a little step back. Uh so I'll do that again. Uh just to say, because I don't think we've said this yet. Um, there are research projects happening globally to sort of try out what genomics in newborn screening might look like. And of those, some programs are looking for hundreds of conditions at once. So just to emphasize, no one is wholesale sequencing newborns yet and just reporting every single thing.

SPEAKER_03Like no one's kind of walking around with it on a USB or a solid straight drive or anything like that. That's definitely how it's in the context of a screening program. Uh, but your question is really important. And so some of it obviously will depend on how we do this. So uh some programs might look for a lot. Obviously, you know, typically a clinical model of consent has involved us explaining in detail why we want to do something, why we think it's in someone's best interests, what the test might involve, what it might find, and what you can do as a result.

SPEAKER_03And the solution in a context where you're looking for lots of things at the same time is not to try and amplify that approach because that will not be successful. And so, uh, and you know, this is not new in the newborn screening context. This is kind of a continuation of a literature that's been going on globally for a long time around kind of consent and complexity, including in genomics. And uh one approach is to be led by the goal. So talk in not just about you know what this test is and what it will involve and how DNA works and all that kind of thing, is to instead say this is why we're offering you this test.

SPEAKER_03And these are broadly some of the things that we can find. And this is why we're offering the information we're offering. This is how we got to our decision about what to look for. So just be transparent about that. And in a paper that I was one of the Authors on that Barth and Knoppers and others wrote that came out in the European Journal of Human Genetics a couple of or just start of last year, we talked about appropriate consent to genomic newborn screening.

SPEAKER_03And it was kind of building in on a model that Julian Copeland and others had developed for the clinical context, but we sort of adapted it for population screening. And it was a way of really trying to take a more top-down approach to consent and yeah, explain it in a way that kind of engages people with why the test's being offered and what might happen as a result, rather than a really granular condition by condition explanation.

SPEAKER_02So we're not giving them a list of a hundred and they've just got the name and the DNA sequence and going tick or no.

SPEAKER_03Yeah, I mean it's not like a it's not like a menu where you kind of you know tick things off.

SPEAKER_02Yeah.

SPEAKER_03I mean, certainly at least not in a formal systemic population screening program because generally it is a program and differentiating choice within the context of formal publicly funded screening is going to make it more complex. So but I think there definitely will be globally offers of newborn screening that are more in that precision health framework where people will get the opportunity to get their fries with their burger, you know, if they want. So um, yeah. So but I also think consent will differ depending on how genomics, if at all, gets rolled out in newborn screening.

SPEAKER_03And so part of it is to respond to the program that is being offered.

SPEAKER_01I imagine it's not most people don't think that you don't you need to understand like literal every sing every single condition to to consent to something, right? Because already, as you mentioned, we already have newborn screening. Uh we we take a bit of uh a tiny little blood sample and we tell the parents, look, we're gonna take a tiny little blood sample. Should we?

SPEAKER_02Do we tell the parents? Depends where you live. Okay, keep going. Depends where you live.

SPEAKER_01Right. Uh okay. Uh or we don't tell them at all. Yeah. Then consent is not an issue.

SPEAKER_03Uh but it is newborn screening is mandated in a handful of countries globally. All right.

SPEAKER_01I'm gonna ask a more dangerous question. If that's already mandated in a bunch of uh countries, why bother of consent at all with this new thing? If it's basically the same thing plus a little bit.

SPEAKER_02Are you making a mandate for expansive screening based on the right of the ace to in somatic at-wrist child to be found, Ainsley? Is that what you're really saying?

SPEAKER_03Good segue.

SPEAKER_01What a way to try to like convert that into like one of the listed questions.

SPEAKER_02Don't call me out. They don't need to know.

SPEAKER_03Uh I now don't know which question I should answer, but I think um just to go back to that point about hey, where you said this is no different to what's come before, and we're just adding some stuff on. So why, if it's mandated in certain places, shouldn't we just add this as well and carry on? So, at slight risk of completely contradicting myself from what I said earlier, uh I'll say two things. One is that um I am in camp engagement and consent about newborn screening. So in Australia, we do seek consent.

SPEAKER_03It's not perfect, but I think it helps increase the transparency of the program. And I think particularly in a post-COVID world where trust in health is lower than it was, I think it's important to be transparent and to seek engagement. Um, so I but you know, countries where it is mandated, you know, that's how they do it. And they do it more because of the umbrella that it is population screening, public health intervention. And typically they come, you know, countries where you put fluoride in the water or uh do things like that, we don't seek individual consent to that.

SPEAKER_03You know, we do a lot of mandated health intervention in a way where we don't seek consent. So yeah, so I think we should have consent. And I it isn't perfect, and I we've got work to do, but I think it's worth pursuing. I said I was going to say two things, I can no longer remember what the second one was. So I'll say something else and pretend it was the second thing I was going to say, which was um I think even though I said earlier, nothing to see here, genomics is kind of a continuation, we can't be genomic exceptionists.

SPEAKER_03I think where things might depart is if we do store the data, because there is um data security considerations, it's quite sensitive data, it's what my colleague Gabe Watts and I have called diagnostically durable over time. You know, like a biochemical result is something that's a phenotype at a point in time, whereas a genotype more or less stays static. And while the quality of that sequencing information might change if you sequence in 10 years compared to now, the actual base pairs more or less will remain the same.

SPEAKER_03So I think there are some sensitivities, particularly because we were talking about its shininess and its hype. And, you know, I think if people found out that they were having a genomic test done on their newborn that they didn't know about, that would be very bad for existing highly trusted, proven newborn screening. And I think it would put the program at risk. At the same time, though, consent and doing it well might be a reason to actually be more prudent and constrained with an offer of wide-scope genomic newborn screening.

SPEAKER_03And that was a point we sort of tried to make in a nuanced way in that paper that has to do with the right of the asymptomatic at-risk child to be found, which is a right that Bartha Knoppers developed and which we wrote and expanded upon in that paper. And um, so it could sound like a mandate for expansive screening, but we actually kind of meant the opposite, which was a mandate to protect those children who are going to get very sick without newborn screening.

SPEAKER_03It's not a mandate to find every child that could be found with every single thing, like um, you know, a asymptomatic at-risk child. Yes, and it's those words have to be read as connected words. So it's not just asymptomatic, not just at risk, and not just a child. It is all three. So it's not about finding something that will happen when they're 30. It's not about carrier status to inform their parents' future decision making, although that is something that is relevant to newborn screening and should be considered alongside what might happen to the newborn.

SPEAKER_03So it's kind of a misreading of the argument to say it's expansive because we were saying actually, if we're going to use genomics, we need to use it well. And we need to not make the whole thing so complex, including consent, that actually it means people start saying no. And then the whole idea of why newborn screening exists in the first place is unsettled.

SPEAKER_02So genomic screening needs to be used in a way that makes what we're already doing more efficient and more accurate, rather than just making it wider but maybe less accurate, accurate, and less efficient, and just more costly all round.

SPEAKER_03100%.

SPEAKER_02Awesome.

SPEAKER_01So when Bill Gates starts putting 5G into our genes through a genomic screening screening, what are you gonna say to parents? What do you have to say for yourself?

SPEAKER_03I'm gonna say the same thing I said to your earlier comment, and I'm gonna say when that happens, I'll come back and talk to you about it again.

SPEAKER_02We've got time for one last question. I always said I had one last question before. This always happens, but uh with newborn screening at a crossroads and where we are now, taking everything we've talked about into consideration, what ethical values do you think we need to prioritize right now?

SPEAKER_03I gave you this question to ask me, and do you think I really prepared an answer to it? Nope.

SPEAKER_01I called you out for for asking the question that was, you know, for shoehorning it in. Yeah. And now you've called yourself out.

SPEAKER_03I will have, I will have some things to say about it. The first thing I will say is um I think the values to me that are really important here are the ones that can be overlooked in the rush to implement a shiny new technology. And they are values that come more from uh screening ethics, public health ethics than say autonomy, empowerment, those types of values slash principles. So I think one that's really important is solidarity. And that's like empathy and shared understanding.

SPEAKER_03It's about um putting ourselves in the shoes of the people that we want to help. So we want to really think about what it's like for a newborn to grow up with certain kinds of information and what that might be like for them. We want to really put ourselves in the shoes of the parents who are going to be asked to use this technology or asked to use this test and have this test and see how they feel about it. We need to think about the newborns once they're 16 and if we're going to keep that data over time, seeking their permission to continue to keep it, and so on.

SPEAKER_03So, and a concept like solidarity does a lot of work for us because it helps us really understand the messy complexity of doing programmatic screening. It's not just about test information, great. You know, it builds in a lot of other considerations alongside that. And I think another value, and you know, whether it's a value, I guess, is debatable, but something we need to think about because it's important is harm. And that does a lot of work for us because I think one of the greatest challenges here, going back to what I talked about right at the start, with people, lots of people undiagnosed with rare conditions, is how do we, how can we trade off those benefits for people that are found with the potential of finding people that don't need to be found?

SPEAKER_03And we cannot know that in advance. And it's this kind of idea of um actual versus statistical lives and that value trade-off between which lives do we prioritize and you know, those harms that are slightly more amorphous and and harder to, they're not tangible because they're happening to someone else. And we know in screening, from lots of work that's happened in screening, not necessarily just in genomics, that everyone finds it really hard to step out of their own experience and to actually can to understand to really empathize what it would be like to have screening-related harm and how that matters.

SPEAKER_03And I think we've we haven't done enough work on that yet. So they're the two things that I think I would be really wanting to unpack a bit more is you know, taking that sort of solidaristic, messy complexity and also really thinking carefully about screening-related harm and how that can be used to make sure we offer genomics well as and when we offer it in newborn screening.

SPEAKER_02Great, helpful. I look forward to seeing the research.

SPEAKER_01And Taylor Swift, we're in the comments.

SPEAKER_02Can we fade out with blank space instead of the normal float? Nice to see what no, we don't need to do that. Also, we don't have copyright. Anyway, moving on. Thanks, Ainsley. Thank you.

SPEAKER_00Thanks for listening to our new podcast. Subscribe online and tune in every first of the month. In the meantime, listen to CBME and you and be savvy.

Open the transcript file

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. Can Nihilism Improve Your Mental Wellbeing?

    Nov 2, 202645 minAudio

    Send us Fan Mail We spend much of our lives searching for meaning. Some of us look for it at work. Some in our families and friends. Some look for it at an overpriced spiritual retreat in Bali where some dude named...

    Credit the people on this episode

  2. Insurance Discrimination: Is it Fair? with Harisan Nasir

    Sep 24, 202649 minAudio

    Send us Fan Mail In some insurance scheme, you might be required to pay more because you are more prone to disability. In another, you may have to pay more because you're a woman (and are statistically likely to live...

    Credit the people on this episode

  3. The Hidden Side of Birth: Injury, Trauma, and PTSD with Angela Ballantyne

    Jul 2, 202648 minAudio

    Send us Fan Mail Did you know that over 80% of people who give birth experience an injury? That anywhere between 30 and 50% of people who give birth find it traumatic? And that up to 15% of people experience PTSD from...

    Credit the people on this episode

  4. Brains in Jars with Insoo Hyun

    Jun 1, 202656 minAudio

    Send us Fan Mail Could a blob of cells in a petri dish one day think? Feel? Have rights? In this episode, Professor Insoo Hyun (Harvard Medical School, one of the world's leading experts on the ethics of stem cell and...

    Credit the people on this episode

  5. To smoke or to vape? With Johannes Kniess

    May 14, 202654 minAudio

    Send us Fan Mail In this episode, guest-host Kat Muyskens and Sinead chat with Dr. Johannes Kniess from Newcastle University (UK) about what governments are legitimately allowed to make us do, whether we like it or not....

    Credit the people on this episode